EugeneBraunwaldMD

Cardiology • Boston, MA

Adult Congenital Heart Disease

Hersey Distinguished Professor of the Theory and Practice of Physic, Brigham and Women's Hospital

Join to view full profile

Dr. Braunwald is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Braunwald's full profile

Already have an account?

Office
75 Francis St
Boston, MA 02115
Phone+1 617-732-7477

Fax+1 617-975-0955

Education & Training

Johns Hopkins UniversityResidency, Internal Medicine, 1957 - 1958
SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 1953 - 1954
Icahn School of Medicine at Mount SinaiInternship, Transitional Year, 1952 - 1953
New York University School of MedicineClass of 1952

Certifications & Licensure

MA State Medical License 1972 - 2017

Awards, Honors, & Recognition

Elected Member Institute of Medicine, 1974
Whos Who in Medicine and Healthcare Marquis Whos Who
Elected Member The American Society for Clinical Investigation

Clinical Trials

Thrombolysis in Myocardial Ischemia Trial (TIMI III) Start of enrollment: 1989 Apr 01
Completed
Phase 3
Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome Start of enrollment: 2007 Feb 01
Completed
Phase 2
Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study) Start of enrollment: 2008 Feb 01
Completed
Phase 3
Effectiveness of Surgical Mitral Valve Repair Versus Medical Treatment for People With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure Start of enrollment: 2008 Mar 01
Terminated
Phase 3
A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks Start of enrollment: 2007 Nov 01
Terminated
Phase 2
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study) Start of enrollment: 2008 Sep 01
Completed
Phase 3
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels Start of enrollment: 2010 May 01
Completed
Phase 2
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications Start of enrollment: 2010 May 01
Completed
Phase 4
Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study Start of enrollment: 2010 Aug 01
Completed
Phase 2
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin Start of enrollment: 2010 Oct 01
Completed
Phase 3
Study of Renal Denervation in Patients With Heart Failure Start of enrollment: 2013 Dec 01
Terminated
Phase 2
Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction Start of enrollment: 2014 Apr 01
Completed
Phase 2
Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure Start of enrollment: 2014 Dec 30
Completed
Phase 2
Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF Start of enrollment: 2016 Aug 10
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Mortality after high-risk myocardial infarction over the last 20 years: Insights from the VALIANT and PARADISE-MI trials.
Alberto Foà, Maria A Pabon, Eugene Braunwald, Karola Jering, Muthiah Vaduganathan
European Journal of Heart Failure. 2024-12-18
1 citations
Association of Sacubitril/Valsartan vs Valsartan With Blood Pressure Changes and Symptomatic Hypotension: the PARAGLIDE-HF Trial.
Marat Fudim, Derek D Cyr, Jonathan H Ward, Adrian F Hernandez, Serge Lepage
Journal of Cardiac Failure. 2024-12-01
2 citations
Beyond the classic major cardiovascular event outcome for cardiovascular trials.
Mario Gaudino, Eugene Braunwald, Gregg W Stone
European Heart Journal. 2024-11-21

Journal Articles

Cost-Effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure with Reduced Ejection Fraction
Thomas A Gaziano, Gregg C Fonarow, Eugene Braunwald, JAMA Cardiology
Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines
Nicholas A Marston, Marc P Bonaca, Petr Jarolim, Deepak L Bhatt, Stephen D Wiviott, Eugene Braunwald, Marc S Sabatine, JAMA Cardiology
Managing Stable Ischemic Heart Disease
Elliott M Antman, Eugene Braunwald, The New England Journal of Medicine
Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure
Carol I Duffy, Andrew P Ambrosy, Eugene Braunwald, The New England Journal of Medicine
Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure
Eugene Braunwald, David A Morrow, The New England Journal of Medicine
Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients with Heart Failure with Preserved Ejection Fraction
Gregory D Lewis, David J Whellan, Martin M LeWinter, Margaret M Redfield, Andrew L Smith, Eugene Braunwald, Michael M Givertz, Adrian F Hernandez, Sanjiv J Shah, Horng..., JAMA
JACC State-of-the-Art Review JACC State-of-the-Art Review Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Re...
Eugene Braunwald, MD, ScienceDirect
Original Investigation Fatal or Irreversible Bleeding and Ischemic Events with Rivaroxaban in Acute Coronary Syndrome
William J Gibson, Eugene Braunwald, C Michael Gibson, ScienceDirect
Join now to see all

Lectures

Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
Fatal or Irreversible Bleeding and Ischemic Events with Rivaroxaban in Acute Coronary Syndrome
Harvard Medical School ,Department Of Continuing Education, Boston, Massachusetts - 4/28/2013

Authored Content

Cost-Effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure with Reduced Ejection FractionAugust 2020
Cost-Effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure with Reduced Ejection FractionAugust 2020
Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol GuidelinesAugust 2020
Treatment of HypertensionNovember 2018
Rivaroxaban and Post-Stroke Neurological Outcomes in Patients with Acute Coronary SyndromeFebruary 2018
Clinical Events After Interruption of Anticoagulation in Patients with Atrial Fibrillation: An Analysis from the ENGAGE AF-TIMI 48 Trial☆February 2018
Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients with Multivessel Coronary DiseaseJanuary 2018
Reply Cost-Effectiveness of Long-Term Ticagrelor in Patients with Prior Myocardial Infarction: Analysis by SubgroupsJanuary 2018
Join now to see all

Press Mentions

Dr. Jane Newburger of Harvard Medical School to Receive 2024 Eugene Braunwald Academic Mentorship AwardNovember 6th, 2024
MACE in CV Trials: Has the Outcome Outlived Its Role?October 11th, 2024
News Coverage of NYU Langone Health for Tuesday, May 9, 2023May 10th, 2023
Join now to see all